[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comments and Opinions
January 2006

Liver Enzyme Abnormalities in Patients With Atopic Dermatitis Treated With Mycophenolate Mofetil

Arch Dermatol. 2006;142(1):109-116. doi:10.1001/archderm.142.1.109

Mycophenolate mofetil is approved by the US Food and Drug Administration for the treatment of renal allograft rejection, and recently it has received attention as an alternative steroid-sparing agent in dermatology.1-3 Dose-dependent nausea, vomiting, diarrhea, and abdominal pain are the most commonly encountered adverse effects. Bone marrow suppression and increased risk of infection are the major safety risks, and mycophenolate mofetil is generally thought to be free of hepatotoxic effects. Herein, we describe 2 patients with atopic dermatitis who developed increased levels of serum hepatic transaminases (liver function tests) following an increase in dosage of mycophenolate mofetil.